Neuromuscular

As neurologists and other specialists may increasingly be called upon to serve as general hospitalists in the wake of the COVID-19 pandemic, keeping health care workers healthy becomes paramount.

The spine surgeon in the Center for Spine Health at Cleveland Clinic spoke to the importance of improving patient-reported outcomes and ensuring consistent communication with patients undergoing spine surgery.

The chief executive officer of Clene Nanomedicine discussed CNM-Au8, their novel investigational drug that will be used in the world’s first platform trial of potential ALS treatments.

Gaboxadol is the first treatment in 50 years associated with positive change in outcomes in Angelman syndrome.

The president and founder of Cure Rare Disease discussed the company’s custom therapeutics for patients with rare diseases, including the use of CRISPR gene-editing technology to develop treatments for Duchenne muscular dystrophy.

Understanding the pathophysiology of myasthenia gravis is still being determined to this day, but the neonatal Fc receptor is emerging as a potential treatment.

The Healey ALS Platform Trial learns from successful cancer drug studies to identify and accelerate new treatments for the devastating disease.

Neurology News Network for the week ending February 22, 2020.

In addition to significant improvements compared to placebo on Quantitative QMG scores, zilucoplan improved patients' activities of daily living and quality of life scores.

The Prometra II offers a pressure-driven, valve-gated delivery mechanism that allows for novel programming modes of intermittent flow followed by periods of no flow—a feature unique to this device.

The announcement formally connects Bcureful and the Tuberous Sclerosis Alliance together after working closely together for over the past 8 years.

The revision accounts for data from the NURTURE trial showing that patients with 3 copies of SMN2 greatly benefit from early treatment.

The Tuberous Sclerosis Alliance has announced updates to access of everolimus, a drug used to treat several conditions associated with tuberous sclerosis complex.

Neurofilament light chain has emerged as a biomarker with utility across the breadth of neurology, but just how much can it actually help?